Sign up to save your podcasts
Or
Share How to Treat Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Targeted Mutations
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
How to Treat Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Targeted Mutations
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Mark Awad, a world-renowned thoracic medical oncologist from Memorial Sloan Kettering. Together, they dived deep into the treatment landscape for metastatic non-small cell lung cancer (NSCLC) without actionable mutations in frontline settings.
Episode Highlights:
• The importance of next-generation sequencing (NGS) and PD-L1 levels in treatment decision-making.
• Current treatment options for patients with high PD-L1 scores, including single-agent immunotherapy.
• Strategies for patients with low or intermediate PD-L1 scores, including chemotherapy combined with immunotherapy.
• Discussed KRAS G12C and HER2 positive disease in second-line settings, including the latest approved therapies.
• Insights into the potential side effects and considerations when transitioning from immunotherapy to targeted therapies.
Join us as we explored the complexities of treating metastatic NSCLC and the ongoing need for clinical trials and biomarker discovery. Don't forget to check out our other episodes for more insights on treatment algorithms and recent FDA approvals!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
View all episodes
By Oncology Brothers
4.8
3636 ratings
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Mark Awad, a world-renowned thoracic medical oncologist from Memorial Sloan Kettering. Together, they dived deep into the treatment landscape for metastatic non-small cell lung cancer (NSCLC) without actionable mutations in frontline settings.
Episode Highlights:
• The importance of next-generation sequencing (NGS) and PD-L1 levels in treatment decision-making.
• Current treatment options for patients with high PD-L1 scores, including single-agent immunotherapy.
• Strategies for patients with low or intermediate PD-L1 scores, including chemotherapy combined with immunotherapy.
• Discussed KRAS G12C and HER2 positive disease in second-line settings, including the latest approved therapies.
• Insights into the potential side effects and considerations when transitioning from immunotherapy to targeted therapies.
Join us as we explored the complexities of treating metastatic NSCLC and the ongoing need for clinical trials and biomarker discovery. Don't forget to check out our other episodes for more insights on treatment algorithms and recent FDA approvals!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
Breast Cancer Update
63 Listeners
Journal of Clinical Oncology (JCO) Podcast
41 Listeners
Research To Practice | Oncology Videos
114 Listeners
The NPR Politics Podcast
25,756 Listeners
ASCO Daily News
56 Listeners
The Curbsiders Internal Medicine Podcast
3,314 Listeners
Core IM | Internal Medicine Podcast
1,090 Listeners
OncoPharm
184 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
21 Listeners
The Clinical Problem Solvers
508 Listeners
Run the List
243 Listeners
Oncology Today with Dr Neil Love
53 Listeners
Two Onc Docs
166 Listeners
Blood Cancer Talks
48 Listeners